<DOC>
	<DOC>NCT01800045</DOC>
	<brief_summary>Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks per week). The patients will be treated during 7 weeks with Pitolisant or placebo.</brief_summary>
	<brief_title>Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)</brief_title>
	<detailed_description>The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by verifying whether the results of Pitolisant are superior to those of placebo. The safety will also be assessed.</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Cataplexy</mesh_term>
	<criteria>Main Narcoleptic with cataplexy : at least 3 weekly cataplexy attacks ESS &gt; or = 12 ICF signed and dated Main Other conditions that could generate EDS Psychological and neurological disorders Acute or chronic severe disease Treatment by prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Narcolepsy</keyword>
	<keyword>Cataplexy</keyword>
	<keyword>Sleep disorder</keyword>
	<keyword>Excessive daytime sleepiness</keyword>
</DOC>